EDIL3 and prostate carcinoma: According to [67, 68], paclitaxel resistance is strongly associated with high expression levels of EDIL3. Knockdown of EDIL3 by targeting the RGD motif induces the responsiveness of breast cancer and prostate cancer cells toward paclitaxel.